A Phase 1, Open Label, Dose Escalation Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Subjects With Relapsed or Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs BIIB 022 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Biogen
- 06 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jan 2011 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 03 Feb 2010 Planned end date changed from 1 May 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.